2024
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases
Pach J, Valido K, Belzer A, Leventhal J. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases. American Journal Of Clinical Dermatology 2024, 25: 595-607. PMID: 38767827, DOI: 10.1007/s40257-024-00866-z.Peer-Reviewed Original ResearchCutaneous immune-related adverse eventsImmune-related adverse eventsAdverse eventsAntitumor responseBiological agentsHigh-dose systemic corticosteroidsSevere cutaneous adverse reactionsImmune checkpoint inhibitorsStevens-Johnson syndromeCutaneous adverse reactionsAdverse event patternEnglish-language literatureTransient acantholytic dermatosisTreating high-gradeSpectrum of dermatologic manifestationsCheckpoint inhibitorsSystemic corticosteroidsCorticosteroid-sparingImmunobullous disordersPsoriasiform eruptionLichenoid reactionsEczematous dermatitisLichenoid eruptionDermatological manifestationsHigh-grade
2023
The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy
Belzer A, Mortlock R, Pach J, Cohen J, Leventhal J. The effect of baseline eczema or psoriasis on the morphology of cutaneous immune-related adverse events due to immune checkpoint inhibitor therapy. Journal Of The American Academy Of Dermatology 2023, 88: 1198-1200. PMID: 36634749, PMCID: PMC10121758, DOI: 10.1016/j.jaad.2023.01.002.Peer-Reviewed Original ResearchConceptsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyImmune-related adverse eventsCheckpoint inhibitor therapyAdverse eventsInhibitor therapyPsoriasisEczemaTherapy
2022
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Pach J, Leventhal J. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. Critical Reviews In Immunology 2022, 42: 1-20. PMID: 37022356, DOI: 10.1615/critrevimmunol.2023046895.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCheckpoint inhibitorsT cellsAdverse eventsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyInhibition of T cellsOveractivation of T cellsCheckpoint inhibitor therapyImmune checkpoint inhibitorsCutaneous adverse eventsStevens-Johnson syndromeCutaneous autoimmune diseasesToxic epidermal necrolysisPre-existing diseaseLife-threatening eruptionsInhibitor therapyTreatment interruptionImmune dysregulationImmune surveillanceMaculopapular eruptionEpidermal necrolysisAutoimmune diseasesBullous dermatosisAntitumor activity